110 related articles for article (PubMed ID: 10768840)
1. Characterization of the CD30L binding domain on the human CD30 molecule using anti-CD30 antibodies.
Franke AC; Jung D; Ellis TM
Hybridoma; 2000 Feb; 19(1):43-8. PubMed ID: 10768840
[TBL] [Abstract][Full Text] [Related]
2. Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma.
Huhn M; Sasse S; Tur MK; Matthey B; Schinköthe T; Rybak SM; Barth S; Engert A
Cancer Res; 2001 Dec; 61(24):8737-42. PubMed ID: 11751393
[TBL] [Abstract][Full Text] [Related]
3. Reverse signaling via CD30 ligand.
Wiley SR; Goodwin RG; Smith CA
J Immunol; 1996 Oct; 157(8):3635-9. PubMed ID: 8871664
[TBL] [Abstract][Full Text] [Related]
4. Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines.
Gruss HJ; DaSilva N; Hu ZB; Uphoff CC; Goodwin RG; Drexler HG
Leukemia; 1994 Dec; 8(12):2083-94. PubMed ID: 7528856
[TBL] [Abstract][Full Text] [Related]
5. CD30 antigen: not a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between TH1/TH2 response.
Pellegrini P; Berghella AM; Contasta I; Adorno D
Transpl Immunol; 2003; 12(1):49-61. PubMed ID: 14551032
[TBL] [Abstract][Full Text] [Related]
6. Construction and expression of a soluble form of human CD30 ligand with functional activity.
Powell IF; Li T; Jäck HM; Ellis TM
J Leukoc Biol; 1998 Jun; 63(6):752-7. PubMed ID: 9620669
[TBL] [Abstract][Full Text] [Related]
7. CD30 ligand/CD30 plays a critical role in Th17 differentiation in mice.
Sun X; Yamada H; Shibata K; Muta H; Tani K; Podack ER; Yoshikai Y
J Immunol; 2010 Aug; 185(4):2222-30. PubMed ID: 20639486
[TBL] [Abstract][Full Text] [Related]
8. Deciphering CD30 ligand biology and its role in humoral immunity.
Kennedy MK; Willis CR; Armitage RJ
Immunology; 2006 Jun; 118(2):143-52. PubMed ID: 16771849
[TBL] [Abstract][Full Text] [Related]
9. Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4).
Horn-Lohrens O; Tiemann M; Lange H; Kobarg J; Hafner M; Hansen H; Sterry W; Parwaresch RM; Lemke H
Int J Cancer; 1995 Feb; 60(4):539-44. PubMed ID: 7530238
[TBL] [Abstract][Full Text] [Related]
10. CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues.
Gruss HJ; Pinto A; Gloghini A; Wehnes E; Wright B; Boiani N; Aldinucci D; Gattei V; Zagonel V; Smith CA; Kadin ME; von Schilling C; Goodwin RG; Herrmann F; Carbone A
Am J Pathol; 1996 Aug; 149(2):469-81. PubMed ID: 8701986
[TBL] [Abstract][Full Text] [Related]
11. Critical roles of CD30/CD30L interactions in murine autoimmune diabetes.
Chakrabarty S; Nagata M; Yasuda H; Wen L; Nakayama M; Chowdhury SA; Yamada K; Jin Z; Kotani R; Moriyama H; Shimozato O; Yagita H; Yokono K
Clin Exp Immunol; 2003 Sep; 133(3):318-25. PubMed ID: 12930356
[TBL] [Abstract][Full Text] [Related]
12. CD30 ligand in lymphoma patients with CD30+ tumors.
Younes A; Consoli U; Snell V; Clodi K; Kliche KO; Palmer JL; Gruss HJ; Armitage R; Thomas EK; Cabanillas F; Andreeff M
J Clin Oncol; 1997 Nov; 15(11):3355-62. PubMed ID: 9363866
[TBL] [Abstract][Full Text] [Related]
13. Expression of CD30 ligand (CD153) on murine activated T cells.
Shimozato O; Takeda K; Yagita H; Okumura K
Biochem Biophys Res Commun; 1999 Mar; 256(3):519-26. PubMed ID: 10080930
[TBL] [Abstract][Full Text] [Related]
14. A critical role of CD30 ligand/CD30 in controlling inflammatory bowel diseases in mice.
Sun X; Somada S; Shibata K; Muta H; Yamada H; Yoshihara H; Honda K; Nakamura K; Takayanagi R; Tani K; Podack ER; Yoshikai Y
Gastroenterology; 2008 Feb; 134(2):447-58. PubMed ID: 18242212
[TBL] [Abstract][Full Text] [Related]
15. Expression of tumour necrosis factor (TNF) ligand superfamily co-stimulatory molecules CD30L, CD27L, OX40L, and 4-1BBL in murine hearts with acute myocarditis caused by Coxsackievirus B3.
Seko Y; Takahashi N; Oshima H; Shimozato O; Akiba H; Takeda K; Kobata T; Yagita H; Okumura K; Azuma M; Nagai R
J Pathol; 2001 Dec; 195(5):593-603. PubMed ID: 11745696
[TBL] [Abstract][Full Text] [Related]
16. Proliferation of CD30+ T-helper 2 lymphoma cells can be inhibited by CD30 receptor cross-linking with recombinant CD30 ligand.
Willers J; Dummer R; Kempf W; Kündig T; Burg G; Kadin ME
Clin Cancer Res; 2003 Jul; 9(7):2744-54. PubMed ID: 12855655
[TBL] [Abstract][Full Text] [Related]
17. CD30 ligand signal transduction involves activation of a tyrosine kinase and of mitogen-activated protein kinase in a Hodgkin's lymphoma cell line.
Wendtner CM; Schmitt B; Gruss HJ; Druker BJ; Emmerich B; Goodwin RG; Hallek M
Cancer Res; 1995 Sep; 55(18):4157-61. PubMed ID: 7545087
[TBL] [Abstract][Full Text] [Related]
18. CD30L-ETA': a new recombinant immunotoxin based on the CD30 ligand for possible use against human lymphoma.
Barth S; Matthey B; Huhn M; Diehl V; Engert A
Cytokines Cell Mol Ther; 1999 Jun; 5(2):69-78. PubMed ID: 10515679
[TBL] [Abstract][Full Text] [Related]
19. Expression of CD30 ligand and CD30 receptor in normal thyroid and benign and malignant thyroid nodules.
Trovato M; Villari D; Ruggeri RM; Quattrocchi E; Fragetta F; Simone A; Scarfi R; Magro G; Batolo D; Trimarchi F; Benvenga S
Thyroid; 2001 Jul; 11(7):621-8. PubMed ID: 11484890
[TBL] [Abstract][Full Text] [Related]
20. CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin.
Gattei V; Degan M; Gloghini A; De Iuliis A; Improta S; Rossi FM; Aldinucci D; Perin V; Serraino D; Babare R; Zagonel V; Gruss HJ; Carbone A; Pinto A
Blood; 1997 Mar; 89(6):2048-59. PubMed ID: 9058727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]